Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial.

ABSTRACT:

Background

Skin barrier dysfunction precedes eczema development. We tested whether daily use of emollient in the first year could prevent eczema in high-risk children.

Methods

We did a multicentre, pragmatic, parallel-group, randomised controlled trial in 12 hospitals and four primary care sites across the UK. Families were approached via antenatal or postnatal services for recruitment of term infants (at least 37 weeks' gestation) at high risk of developing eczema (ie, at least one first-degree relative with parent-reported eczema, allergic rhinitis, or asthma, diagnosed by a doctor). Term newborns with a family history of atopic disease were randomly assigned (1:1) to application of emollient daily (either Diprobase cream or DoubleBase gel) for the first year plus standard

SUBMITTER: Chalmers JR 

PROVIDER: S-EPMC7086156 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature